Exploratory Study of Ultrasound Signs of Native Septic Arthritis of the Knee
NCT ID: NCT04952220
Last Updated: 2024-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2021-10-27
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary endpoint: Describe the ultrasound abnormalities observed on Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasonography Assessment of Septic Arthritis on Native Joint
NCT02018952
Synovial Proliferation on Routine Ultrasound: Active or Inactive?
NCT06809972
Quantitative Assessment of Distal Radioulnar Joint Stability With Pressure-Monitor Ultrasonography
NCT03658096
Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae
NCT04896476
Study of Arterial Properties by Ultra-high Frequency Ultrasound in Fibromuscular Dysplasia and Vascular Ehlers-Danlos Syndrome
NCT03596437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Search for poor prognostic factors in native septic arthritis of the knee.
2. To look for an association between initial sonographic factors and the use of joint lavage.
3. Look for associations between sonographic signs and clinico-radio-biologic factors at each visit (D10, 6 weeks, 3 months and 6 months)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
native septic arthritis of the knee
Describe the ultrasound abnormalities observed at D0, D10 or before surgery, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee:
thickness and vascularity of the synovial membrane, existence and measurement of joint effusion existence of articular partitioning, erosions and adjacent soft tissue involvement (muscle abscess, cellulitis)
ultrasound
Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ultrasound
Describe the sonographic abnormalities observed at Day 0, Day 10, 6 weeks, 3 months, 6 months, during native septic arthritis of the knee
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Bacteriologically proven native septic arthritis
* Meets the definition of septic arthritis: Bacteriological documentation of joint puncture fluid-Native articulation
* Free subject, without guardianship or trusteeship, or subordination
* Non-opposition of the patient after clear and fair information about the study
Exclusion Criteria
* Arthritis with Mycobacterium Tuberculosis.
* Patients benefiting from a reinforced protection, namely: minors, pregnant and/or breast-feeding women, persons deprived of liberty by a judicial or administrative decision, adults under legal protection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GERVAIS Elisabeth
Role: PRINCIPAL_INVESTIGATOR
Poitiers University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nantes
Nantes, Pays de la Loire Region, France
CH D'Angouleme
Angoulême, , France
CH de La roche-sur-yon
La Roche-sur-Yon, , France
CH De La Rochelle
La Rochelle, , France
CH de Niort
Niort, , France
CHU de Poitiers
Poitiers, , France
CHU de Rennes
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A01301-40
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.